|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
|
28067908 |
2017 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.
|
28067908 |
2017 |
|
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
|
26192919 |
2015 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations.
|
26192919 |
2015 |
|
Hypercholesterolemia, Familial
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Low-density lipoprotein receptor mutations generate synthetic genome-wide associations.
|
22968135 |
2013 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.
|
23749187 |
2013 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
|
21833088 |
2011 |
|
Multiple Sclerosis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
|
21833088 |
2011 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Structural optimization and structure-activity relationship (SAR) analysis were then carried out on the virtual hit of VS-8 with potent activity, which resulted in the discovery of compound 10 as a more potent regulator of Hsp90-Cdc37 interaction with a promising inhibitory effect (IC<sub>50</sub> = 27 μM), a moderate binding capacity (K<sub>D</sub> = 40 μM) and a preferable antiproliferative activity against several cancer lines including MCF-7, SKBR3 and A549 cell lines (IC<sub>50</sub> = 26 μM, 15 μM and 38 μM respectively).
|
28482218 |
2017 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Structural optimization and structure-activity relationship (SAR) analysis were then carried out on the virtual hit of VS-8 with potent activity, which resulted in the discovery of compound 10 as a more potent regulator of Hsp90-Cdc37 interaction with a promising inhibitory effect (IC<sub>50</sub> = 27 μM), a moderate binding capacity (K<sub>D</sub> = 40 μM) and a preferable antiproliferative activity against several cancer lines including MCF-7, SKBR3 and A549 cell lines (IC<sub>50</sub> = 26 μM, 15 μM and 38 μM respectively).
|
28482218 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Putative biomarkers such as cell cycle related genes (Cdc37), cancer cell adhesion (Glycam 1, integrin alpha8, integrin alphaX and Clec4n), signal transduction (Tlr2, IL-33, and Ccbp2), migration (Ccr1, Ccl6, and diaphorase 1 (Cyb5r3) and cancer development (epiregulin) can be useful for diagnosis and as prognosis markers and some of the target molecules can be applied for prevention of cancer.
|
19082487 |
2009 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Furthermore, CDC37 silencing sensitises cancer cells to HSP90 inhibitors by potentiating kinase client depletion and the induction of apoptosis, suggesting that simultaneously modulating HSP90 and CDC37 could be beneficial.
|
19177013 |
2009 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
These results support an essential role for CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therapeutic potential of targeting CDC37 in cancer.
|
18931700 |
2009 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Putative biomarkers such as cell cycle related genes (Cdc37), cancer cell adhesion (Glycam 1, integrin alpha8, integrin alphaX and Clec4n), signal transduction (Tlr2, IL-33, and Ccbp2), migration (Ccr1, Ccl6, and diaphorase 1 (Cyb5r3) and cancer development (epiregulin) can be useful for diagnosis and as prognosis markers and some of the target molecules can be applied for prevention of cancer.
|
19082487 |
2009 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Furthermore, CDC37 silencing sensitises cancer cells to HSP90 inhibitors by potentiating kinase client depletion and the induction of apoptosis, suggesting that simultaneously modulating HSP90 and CDC37 could be beneficial.
|
19177013 |
2009 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
These results support an essential role for CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therapeutic potential of targeting CDC37 in cancer.
|
18931700 |
2009 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In contrast to HSP90-directed agents, Cdc37 targeting seems to affect cancer cells through a distinct mechanism and does not significantly deplete the intracellular levels of most known HSP90 client proteins.
|
18089825 |
2007 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
In contrast to HSP90-directed agents, Cdc37 targeting seems to affect cancer cells through a distinct mechanism and does not significantly deplete the intracellular levels of most known HSP90 client proteins.
|
18089825 |
2007 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Hsp90 and Cdc37 -- a chaperone cancer conspiracy.
|
15661534 |
2005 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Hsp90 and Cdc37 -- a chaperone cancer conspiracy.
|
15661534 |
2005 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
These findings indicate that CDC37, a crucial protein in prostate cancer progression, is regulated reciprocally by MZF1 and SCAND1.
|
31181782 |
2019 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
MZF1 became bound to these regulatory sites and <i>trans</i>-activated the <i>CDC37</i> gene whereas MZF1 depletion decreased CDC37 transcription and reduced the tumorigenesis of prostate cancer cells.
|
31181782 |
2019 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
High levels of RUVBL2 promoted carcinogenesis through the heat shock protein 90 (HSP90)-Cell Division Cycle 37 (CDC37), AKT serine/threonine kinase (AKT) and mitogen-activated protein kinase (ERK/MAPK) pathways.
|
31572066 |
2019 |